Literature DB >> 21158973

The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.

A Cerami1.   

Abstract

The hurtful feelings associated with failing can be devastating especially if the failure occurs after the investment of a considerable effort. The reflection of a lifetime of work in translational medicine has revealed that the study of failures can give birth to new insights that can be explored with important consequences. This article discusses the analysis of two failures that have led to remarkable discoveries. The first led to the discovery of TNF as an important mediator of inflammation that can, if unchecked, cause severe damage in mammals. The second is the identification of erythropoietin as the natural inhibitor of the production and biological activity of TNF. I hope that this paper will help give students the courage to persist in looking for the insights that are the by-products of failure, and to understand the long time lines in the path of discoveries.
© 2010 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21158973     DOI: 10.1111/j.1365-2796.2010.02319.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  14 in total

Review 1.  Molecular basis of applied biological therapeutics.

Authors:  U Andersson; K J Tracey
Journal:  J Intern Med       Date:  2011-01       Impact factor: 8.989

Review 2.  A model for lupus brain disease.

Authors:  Betty Diamond; Bruce T Volpe
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  TNF biology, pathogenic mechanisms and emerging therapeutic strategies.

Authors:  George D Kalliolias; Lionel B Ivashkiv
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

4.  A surprising journey in translational medicine.

Authors:  Anthony Cerami
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 5.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

6.  A Journey in Science: The Privilege of Exploring the Brain and the Immune System.

Authors:  Lawrence Steinman
Journal:  Mol Med       Date:  2016-06-02       Impact factor: 6.354

Review 7.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.

Authors:  Bharat B Aggarwal; Subash C Gupta; Ji Hye Kim
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

Review 8.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

9.  Longitudinal Changes in Protein Carbamylation and Mortality Risk after Initiation of Hemodialysis.

Authors:  Sahir Kalim; Caitlin A Trottier; Julia B Wenger; Josh Wibecan; Rayhnuma Ahmed; Elizabeth Ankers; S Ananth Karumanchi; Ravi Thadhani; Anders H Berg
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-21       Impact factor: 8.237

10.  Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.

Authors:  Sahir Kalim; Hector Tamez; Julia Wenger; Elizabeth Ankers; Caitlin A Trottier; Joseph J Deferio; Anders H Berg; S Ananth Karumanchi; Ravi I Thadhani
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-22       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.